Microbiome: The Missing Link in Neuropsychiatric Disorders - European Medical Journal
×

Browse

Microbiome: The Missing Link in Neuropsychiatric Disorders

| Download as | PDF
12 Mins
Authors:
*Alper Evrensel, Mehmet Emin Ceylan
Disclosure:

The authors have declared no conflicts of interest.

Received:
05.10.16
Accepted:
25.11.16
Citation
EMJ Innov. ;1[1]:83-88.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

The relationship between intestinal microbiota and the brain has been the focus of attention of the scientific world in recent years; >90% of the articles discussing the microbiome have been published only recently.1 There is a strong and bidirectional relationship between the brain and the gut. Gut bacteria communicate with the intestinal epithelium and the immune system cells, with this communication causing many autoimmune, metabolic, and neuropsychiatric diseases. New horizons have been opened in the understanding and treatment of neuropsychiatry disorders. Microbiota dysbiosis can be restored with faecal microbiota transplantation, dietary arrangements, and probiotics. The efficacy of faecal microbiota transplantation in neuropsychiatric disorders is being investigated currently, and through the manipulation of the composition of intestinal bacteria in a conscious way, the treatment of neuropsychiatric disorders may be performed in a cheaper, easier, and natural way in the near future. Searching through the relevant literature on PubMed, EMBASE, and Google Scholar electronic databases, this is one of the first articles to discuss faecal microbiota transplantation in neuropsychiatric disorders in detail.

THE HISTORY OF THE MICROBIOME

The term ‘microbiome’ is used to denote all organisms living in the body and their genetic material; the term ‘microbiota’ is used to denote populations of micro-organisms in the different floras of the body (e.g. intestinal microbiota, vaginal microbiota).1 A total of 380 trillion micro-organisms live in the gut. This number is >10-times the total number of human cells.2 Furthermore, these micro-organisms contain approximately 150-times more genes than in the human genome.3 Élie Metchnikoff was the first to realise the importance of the microbiome to human health, with the Nobel Prize in Physiology or Medicine 1908 awarded to Metchnikoff for his contribution to the understanding of cellular and humoral immunity.4 Two years later, the first article concerning how probiotic bacteria can be used in the treatment of depression was published by Phillips.5 However, interest in this subject only lasted for a short time. Throughout the following years, the relationship between intestinal microbiota and the brain was not studied.

Old Friends

The idea that micro-organisms may not all necessarily be harmful has been remembered again nearly 80 years after publication of Phillips’ article. Strachan6 has argued that there may be a relationship between hygiene (increased use of antibiotics, disinfectant cleaning products, modern lifestyle, and urbanisation) and the increase in the incidence of allergic diseases. Rook7 has looked at the human-microbiota relationship from a broader perspective. He has argued that Homo sapiens have evolved along with ‘the old friends’ in the body, namely micro-organisms, for millions of years.7

The Leaky Gut

The surface of the intestinal mucosa is about 260–300 m2 (almost the size of a tennis court).8 More than 7,000 bacteria subspecies live in this vast area.3 Intestinal bacteria produce active metabolites (neurotrophins and antigens) that affect human cells.9 The mucosa is in constant contact with bacteria and metabolites and the intestinal epithelium and mucus layer act as a physical barrier to bacteria and antigens.10 If microbiota change because of the influence of alcohol and nutrition (dysbiosis), the intestinal epithelial wall will be destroyed; this causes increased epithelial permeability and ‘leaky gut’ occurs. Antigen bacterial metabolites leak into the bloodstream from the weak intestinal epithelium and an immune reaction occurs.11 In addition to leaky gut, subepithelial dendritic cells produce exosome-containing bacterial material. Exosomes reach the brain through the blood and lymph.12

MICROBIOTA–GUT–BRAIN AXIS

Another method of interaction between bacteria and the human body is direct communication. Intestinal bacteria interact with the first step of the cytokine production pathway, the intestinal mucosal cells’ toll-like receptors (TLRs). TLRs are also widely available in neurons.13 Therefore, if the gastrointestinal system is referred to as the largest immune organ,14 the intestinal microbiota is the forgotten organ.15 The vagus nerve is another way of communicating between the gut and brain; any change in the gut is transmitted to the brain by the vagus nerve.16 The possible mechanisms of the effect of the microbiota on the central nervous system are as follows:

  • Microbiota dysbiosis17
  • Antigen bacterial metabolites10
  • Neuroactive bacterial metabolites (e.g. brain-derived neurotrophic factor, synaptophysin, postsynaptic density protein-95 [PSD-95])18,19
  • Immune system activation20
  • Vagus nerve-mediated effects16,21,22

Microbiota studies in neuropsychiatric disorders have revealed surprising results. It is useful to review these studies in detail.

Schizophrenia

Several studies on immune system problems in schizophrenia have been performed. The incidence of rheumatoid arthritis has been found to be low in patients with schizophrenia;14 inflammatory cytokine interleukin (IL)-1 receptor antagonist levels in patients with schizophrenia are high, an occurrence thought to protect the patient from developing rheumatoid arthritis.23

It has been shown that anti-gliadin antibodies and gluten sensitivity are increased in patients with schizophrenia;24 there is also a relationship between non-coeliac gluten sensitivity and diseases such as autism and schizophrenia.25 Casein antibodies are increased in patients with schizophrenia and those positive for casein immunoglobulin G antibody have an 18% greater risk of schizophrenia (positive casein immunoglobulin G is a predictor for schizophrenia).26

Neuroinflammation is considered the starting point for pathogenesis of schizophrenia.27 In germ-free (GF) mice, production of brain-derived neurotrophic factor and N-methyl-D-aspartate (NMDA) 2a decreases.28 Changes in microbiota composition may cause NMDA dysfunction in schizophrenia.29 Minocycline (a second-generation tetracycline) shows an antipsychotic-like effect in rats,30 and is also effective in the treatment of negative symptoms of schizophrenia.31 The positive effect of minocycline in the treatment of schizophrenia may happen through a change in the bacterial composition of the microbiota. In a study comparing serological immune markers between schizophrenia, bipolar disorder, and control groups, it was found that microbial products in the systemic circulation caused immune disorders in the schizophrenia group.32 Through probiotic therapy, inflammation subsides in patients with chronic schizophrenia.33

An interesting experiment with olanzapine (an antipsychotic drug) has been performed. One of two groups of GF mice was given a high fat diet only and the other received olanzapine in addition. At the end of the experiment, no differences were detected in terms of weight gain between the two groups. Olanzapine-related weight gain was not realised due to the lack of intestinal bacteria. In the second phase of the experiment, it was found that olanzapine had an antibiotic-like effect on the bacterial flora.34

Anxiety and Depression

In patients with depression, a chronic and mild inflammation is found. The source of this inflammation may be the leaky gut.35 The relation between the microbiota and mood has been investigated, mostly in animal experiments. Campylobacter jejuni given orally leads to anxiety-like behaviour in mice,36 whereas Bifidobacterium infantis has reduced depressive symptoms in GF mice;37 B. infantis is called a psychobiotic because of its antidepressant effect.38 Probiotic drugs include copious amounts of this bacterium.

The anxiety scores of rats given Bifidobacteria longum and Lactobacillus helveticus have been found to decrease,39 while Lactobacillus farciminis decreases the hypothalamic–pituitary–adrenal axis response to stress in mice.40 In an experiment by Bravo et al.,41 the anxiety and depression scores of mice given Lactobacillus rhamnosus for 28 days decreased. In another experiment, anxiety-like behaviour declined after 21 days of L. helveticus usage. When the same implementation was performed in IL-10 (an immunoregulatory cytokine) knockout mice, anxiety levels did not change.42 This finding shows the influence of the immune system on the gut–brain axis.

Probiotic bacteria increase IL-10 levels in GF mice;43 in experimental animals given Lactobacillus GG, an increase in plasma IL-10 levels was found.44 Antidepressants create an anti-inflammatory effect via IL-1045 and treat depression by acting on monoamines and the immune system. In a double-blind placebo-controlled study with healthy volunteers, the first group was given B. longum and L. helveticus R0052, and the other group received a placebo; urinary-free cortisol levels and anxiety/ depression scores decreased in subjects who received probiotic bacteria.46 The positive effects of probiotics in emotional tasks have also been shown through functional magnetic resonance imaging (MRI).47 Microbiota may additionally play a key role in linking an unhealthy diet and depression.48

Autism

Autism is one of the diseases where the gut–brain axis is mostly studied.49 In autistic mice, increased neuroinflammatory markers have been found,50 while in another experiment, autistic behaviours returned with Bacteroides fragilis; this bacterium has been shown to repair intestinal permeability disorder through cytokine production and tight junction expression. Also, 4-ethylphenyl sulphate (a bacterial metabolite) has been found to result in elevated serum levels in autistic mice. When this metabolite has been given to normal rats, the emergence of autistic behaviours has been observed.51,52 In autistic children, decreased Bifidobacterium species, increased Lactobacillus species,53 and increased Bacteroides species54 have been found. It has also been argued that a high carbohydrate diet increases the production of short-chain fatty acids in the gut, and their release into the systemic circulation leads to autistic behaviour.55

Alcohol Addiction

By weakening the wall of the intestinal mucosa, alcohol eases the release of bacterial antigens into the systemic circulation. These substances induce the secretion of proinflammatory cytokines (IL-1β, IL-8, and IL-18) by binding to TLR-4 and TLR-2 receptors of mononuclear cells in peripheral blood. Few studies have investigated links between microbiota and alcohol abuse, although in a study by Leclercq et al.,56 63 alcohol addicts were investigated. It was found that chronic alcohol consumption increased the levels of IL by activating inflammatory processes. A correlation was found between IL levels and the levels of alcohol consumption and craving.56 In a second study by the same investigators, the role of intestinal permeability in alcohol addiction was examined. Intestinal permeability was found to be commensurate with the severity of alcohol dependence.57

REGULATION OF INTESTINAL MICROBIOTA

There are several ways to treat intestinal microbiota dysbiosis. These are prebiotic drugs, probiotic drugs, activated charcoal, and faecal microbiota transplantation.9,58 A prebiotic enables an intestinal bacterium to become more dominant than other ones. A probiotic gets a special kind of bacteria into the body orally or rectally.1 In a single year, >$1 billion is spent on probiotic drugs in the USA.59 Activated charcoal is used in the treatment of poisoning that occurs after usage of high-dose medication as it prevents absorption from the intestines by binding to toxins. Tablets and capsules are used in reducing complaints of diarrhoea, indigestion, and bloating; these may help to relieve the gastrointestinal system and neuropsychiatric symptoms by binding to toxins secreted by microbiota.9

FAECAL MICROBIOTA TRANSPLANTATION: A RISING STAR IN NEUROPSYCHIATRIC DISORDERS

Stool was used for the first time for treatment purposes in China in the 4th Century,60 and has been applied orally under the name of ‘golden syrup’ or ‘yellow soup’ in the treatment of diarrhoea.58 Interestingly, this technique was forgotten over the centuries and was recalled in 1958. Eiseman et al.61 treated a pseudomembranous enterocolitis case with antibiotic-associated severe diarrhoea through faecal microbiota transplantation (FMT), however nowadays, a very high percentage of publications on FMT are regarding Clostridium difficile infection (CDI) and its treatment. This method has started to be used in the treatment of neuropsychiatric disorders in recent years.58

Preparation and Usage of Faecal Microbiota Transplantation

It is recommended to provide faecal material from a stool bank for transfer.62 If this is not possible, health screening of a donor candidate should be performed.63 The stool should be ≥150 g and fresh.63 The receiver should be given a mild laxative a night before the application and the transplanted stool should stay for ≥4 hours within the patient’s gut. An antidiarrhoeal drug (loperamide) should be given an hour before FMT.58 The preparation of the stool material is as follows: the stool is diluted with water, milk, or saline and it is then mixed with a blender. This stool suspension is filtered with a filter or gauze to separate solid particles and the faecal suspension taken up into syringes.63,64 The stool suspension can be sent to the duodenum through oesophagogastroduodenoscopy and can be applied to the colon through a colonoscopy or enema.63 In three-quarters of cases, colonoscopy or enema has been used. In one-quarter of cases endoscopy has been used.65

Faecal Microbiota Transplantation in Neuropsychiatric Disorders

Information on the application of FMT in major psychiatric disorders is insufficient. In the following neuropsychiatric disorders, the effectiveness of FMT has been examined.

FMT can be an effective therapeutic technique for irritable bowel syndrome,66 with the remission rates of irritable bowel syndrome case series ranging from 36–89%.58 The neurological complaints of three multiple sclerosis patients have disappeared after FMT, and their quality of life has improved.67 It has been reported that autistic children have benefited from FMT and their symptoms have regressed.65 Any Parkinson’s disease cases treated with FMT have not been reported yet. However, the chronic constipation of a patient with Parkinson’s disease has been treated with antibiotic treatment; the patient’s neurological symptoms completely disappeared after antibiotherapy.68

FMT is a reliable, easy, and cost-effective treatment69 and its side effects are usually mild. In some cases, diarrhoea presented a day after FMT application, and only a few cases have reported constipation, gas, and abdominal discomfort.63 In a recently published comprehensive review article, the serious side effect rate was determined to be 2%.70 In this study, FMT was applied to all cases of CDI. In CDI cases, serious side effects such as infection, sepsis, and bowel perforation are more likely to occur, therefore this study does not reflect the neuropsychiatric sample. It can be said that FMT is a much more reliable treatment in cases with a neuropsychiatric disorder however the information obtained from the neuropsychiatric patient sample is composed of a small literary anthology (there were not any randomised controlled trials included). There is a need for more evidence and testing in terms of the effectiveness and reliability of FMT.

FMT is often viewed as an undesirable treatment,64 therefore, some patients respond negatively. Women and young people are more reluctant than men and the elderly to try FMT and 33% of patients are unwilling to pay for FMT.71 As an alternative to FMT, oral capsule treatment has been tried. After centrifuging and placing the stool in swallowable capsules, it is frozen at -80°C. Fifteen frozen capsules per day are taken orally.72

CONCLUSIONS

The impact of bacteria that live in the intestines on human health and especially on neuropsychiatric functions has been the centre of interest in the scientific world over the past 5 years. Studies on the microbiome–brain axis comprise mainly GF mouse experiments and due to the large number of bacteria in the human intestinal microbiota, it is difficult to carry out randomised controlled trials. Scientists uncover new treasures from this ‘gold mine’ every day. The beneficial effects of probiotics have been shown many times in experiments with mice however any positive effect of the probiotic bacteria L. rhamnosus on psychological parameters in healthy volunteers has not been found.73 The micro-organism-immune system–diet–brain relationship will be revealed gradually and in the near future, psychomicrobiotics will be used in the treatment of neuropsychiatric disorders. Additionally, FMT, axis seems to be the missing link that will being a cheap, easy, and reliable treatment provide a full understanding for the treatment of method will be used commonly. The gut–brain neuropsychiatric disorders.

References
Khanna S, Tosh PK. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014;89(1):107-14. Sender R et al. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14(8):e1002533. Lozupone CA et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220-30. Mackowiak PA. Recycling Metchnikoff: probiotics, the intestinal microbiome and the quest for long life. Front Public Health. 2013;1:52. Phillips JPG. The Treatment of Melancholia by the Lactic Acid Bacillus. Br J Psychiatry. 1910;56(234):422-31. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259-60. Rook GA. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: darwinian medicine and the ‘hygiene’ or ‘old friends’ hypothesis. Clin Exp Immunol. 2010;160(1):70-9. Helander HF, Fändriks L. Surface area of the digestive tract - revisited. Scand J Gastroenterol. 2014;49(6):681-9. Evrensel A, Ceylan ME. The Gut-Brain Axis: The Missing Link in Depression. Clin Psychopharmacol Neurosci. 2015;13(3):239-44. Borre YE et al. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014;20(9):509-18. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol. 2013;25(4):488-795. Smythies LE, Smythies JR. Microbiota, the immune system, black moods and the brain melancholia updated. Front Hum Neurosci. 2014;8:720. McCusker RH, Kelley KW. Immuneneural connections: how the immune system’s response to infectious agents influences behavior. J Exp Biol. 2013;216(Pt 1):84-98. Severance EG et al. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res. 2016;176(1):23-35. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688-93. Perez-Burgos A et al. Psychoactive bacteria Lactobacillus rhamnosus (JB-1) elicits rapid frequency facilitation in vagal afferents. Am J Physiol Gastrointest Liver Physiol. 2013;304(2):G211-20. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009;136(6):2003-14. Diaz Heijtz R et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011;108(7):3047-52. Douglas-Escobar M et al. Effect of intestinal microbial ecology on the developing brain. JAMA Pediatr. 2013;167(4):374-9. Round JL et al. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun. 2010;34(3):J220-5. Wang X et al. Evidences for vagus nerve in maintenance of immune balance and transmission of immune information from gut to brain in STM-infected rats. World J Gastroenterol. 2002;8(3):540-5. Borovikova LV et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458-62. Potvin S et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801-8. Jin SZ et al. A study of circulating gliadin antibodies in schizophrenia among a Chinese population. Schizophr Bull. 2012;38(3):514-8. Catassi C et al. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients. 2013;5(10):3839-53. Niebuhr DW et al. Association between bovine casein antibody and new onset schizophrenia among US military personnel. Schizophr Res. 2011;128(1-3): 51-5. Na KS et al. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:277-86. Sudo N et al. Postnatal microbial colonization programs the hypothalamicpituitary-adrenal system for stress response in mice. J Physiol. 2004;558 (Pt 1):263-75. Nemani K et al. Schizophrenia and the gut-brain axis. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:155-60. Dokuyucu R et al. Antipsychotic-like effect of minocycline in the rat model. Int J Clin Exp Med. 2014;7(10):3354-61. Qurashi I et al. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J Psychopharmacol. 2014;28(7):707-8. Severance EG et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res. 2013;148(1-3):130-7. Tomasik J et al. Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial. Biomark Insights. 2015;10:47-54. Morgan AP et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One. 2014;9(12):e115225. Berk M et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200. Lyte M et al. Anxiogenic effect of subclinical bacterial infection in mice in the absence of overt immune activation. Physiol Behav. 1998;65(1):63-8. Desbonnet L et al. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010;170(4):1179-88. Dinan TG et al. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013;74(10):720-6. Messaoudi M et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105(5):755-64. Ait-Belgnaoui A et al. Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology. 2012;37(11): 1885-95. Bravo JA et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA. 2011;108(38):16050-5. Ohland CL et al. Effects of Lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology. 2013;38(9):1738-47. Macpherson AJ, Uhr T. Gut flora-mechanisms of regulation. Eur J Surg Suppl. 2002;(587):53-7. Kopp MV et al. Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-gamma release of mononuclear cells but no in vivo effects in supplemented mothers and their neonates. Clin Exp Allergy. 2008;38(4):602-10. Maes M et al. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int Immunopharmacol. 2005;5(3):609-18. Messaoudi M et al. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2(4):256-61. Tillisch K et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144(7):1394-401. Dash S et al. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry. 2015;28(1):1-6. Luna RA et al. The Brain-GutMicrobiome Axis: What Role Does It Play in Autism Spectrum Disorder? Curr Dev Disord Rep. 2016;3(1):75-81. de Theije CGM et al. Intestinal inflammation in a murine model of autism spectrum disorders. Brain Behav Immun. 2014;37:240-7. Hsiao EY et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-63. Reandon S. Gut-brain link grabs neuroscientists. Nature. 2014;515(7526):175-7. Adams JB et al. Gastrointestinal flora and gastrointestinal status in children with autism–comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011;11:22. Finegold SM et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16(4):444-53. Macfabe DF. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis. 2012;23:19260. Leclercq S et al. Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence. Biol Psychiatry. 2014;76(9):725-33. Leclercq S et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A. 2014;111(42):E4485-93. Evrensel A, Ceylan ME. Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders. Clin Psychopharmacol Neurosci. 2016;14(3):231-7. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008;46 Suppl 2:S67-72. Zhang F et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107(11):1755. Eiseman B et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854-9. Di Bella S et al. Fecal microbiota transplantation: the state of the art. Infect Dis Rep. 2013;5(2):e13. Smits LP et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946-53. Evrensel A, Ceylan ME. The role of fecal microbiota transplantation in psychiatric treatment. Anadolu Psikiyatri Derg. 2015;16(5):380. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29(1):79-84. Pinn DM. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil. 2015;27(1):19-29. Xu MQ et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015;21(1):102-11. Ananthaswamy A. Faecal transplant eases symptoms of Parkinson’s. New Sci. 2011;209(2796):8-9. Evrensel A, Ceylan ME. [The Future of Fecal Microbiota Transplantation Method in Neuropsychiatric Disorders]. Turk Psikiyatri Derg. 2016;27(1):71-2. [Article in Turkish]. Wang S et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016;11(8):e0161174. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78(2):240-9. Youngster I et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772-8. Kelly JR et al. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain Behav Immun. 2016 [Epub ahead of print].